Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes James M. Foran, MD, FRCPC, Jamile M. Shammo, MD, FASCP, FACP The American Journal of Medicine Volume 125, Issue 7, Pages S6-S13 (July 2012) DOI: 10.1016/j.amjmed.2012.04.015 Copyright © 2012 Elsevier Inc. Terms and Conditions
Figure 1 Morphologic features of dysgranulopoiesis can be seen in either a blood or bone marrow aspirate smear: nuclear hyposegmentation, so-called “pseudo-Pelger-Huet” or “Pelgeroid” anomaly. (Reprinted with permission from Hematol Oncol Clin North Am.31) The American Journal of Medicine 2012 125, S6-S13DOI: (10.1016/j.amjmed.2012.04.015) Copyright © 2012 Elsevier Inc. Terms and Conditions
Figure 2 Flow-chart: diagnosis workup and referral of patients with myelodysplastic syndromes (MDS). AI = autoimmune; BM = bone marrow; CBC = complete blood count; EPO = erythropoietin; GI = gastrointestinal; ITP = idiopathic thrombocytopenic purpura; NCCN = National Comprehensive Cancer Network; RBC = red blood cell. The American Journal of Medicine 2012 125, S6-S13DOI: (10.1016/j.amjmed.2012.04.015) Copyright © 2012 Elsevier Inc. Terms and Conditions